OncoMatch

OncoMatch/Clinical Trials/NCT05739981

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Is NCT05739981 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Paclitaxel and Carboplatin for ovarian cancer.

Phase 1/2RecruitingImunonNCT05739981Data as of May 2026

Treatment: Paclitaxel · Carboplatin · Bevacizumab · IMNN-001This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage III, IV

Grade: high grade

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: IMNN-001 (IMNN-001)

Subjects who have received prior treatment with IMNN-001.

Cannot have received: radiation therapy

Exception: Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed more than three years prior to registration, and the subject remains free of recurrent or metastatic disease.

Subjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded.

Cannot have received: chemotherapy

Exception: Subjects may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the subject remains free of recurrent or metastatic disease.

Subjects who have received prior chemotherapy for any abdominal or pelvic tumor are excluded.

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Johns Hopkins Medicine SKCCC · Baltimore, Maryland
  • Memorial Sloan Kettering Cancer Center · New York, New York
  • OU Health, Stephenson Cancer Center · Oklahoma City, Oklahoma
  • University of Texas MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify